Arrowhead Pharmaceuticals Inc. (ARWR) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (41% profit margin, 11% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
Arrowhead Pharmaceuticals Inc. (ARWR) advanced +0.47% to $60.49 as options desks priced 55% call premium vs. 45% put protection around the $59 max-pain magnet. High-quality cash engine (41% profit margin, 11% return on capital) with steady institutional support.
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, hig
The regulatory approval covers patients diagnosed through either genetic testing or clinical criteria.
PASADENA, Calif., October 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS)
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to f
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARWR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARWR. Explore sector supply chains on /butterfly.
Why ARWR Stock advanced +0.47% Today — RQD Quant Desk Flash. High-quality cash engine (41% profit margin, 11% return on capital) with steady institutional support.